Onward Ho! Glenmark Strikes First Onco Asset Deal With China’s Harbour BioMed

 
• By Anju Ghangurde

Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.

Hand shaking
GLENMARK AND HARBOUR BIOMED HAVE FIRMED UP A LICENSING DEAL FOR AN ONCOLOGY ASSET

More from Deals

More from Business